Table 3 Baseline characteristics after propensity score matching
From: Impact of Pneumocystis jirovecii pneumonia on kidney transplant outcome
Variables | PCP negative (n = 118) | PCP positive (n = 68) | P |
|---|---|---|---|
Age (years) | 46.7 ± 14.6 | 48.3 ± 14.4 | 0.504 |
Female (%) | 21.8 | 23.5 | 0.792 |
Body mass index (kg/m2) | 22.5 ± 3.4 | 22.6 ± 2.6 | 0.509 |
Donor type (%) | 0.447 | ||
Living | 64.5 | 58.8 | |
Deceased | 35.5 | 41.2 | 0.846 |
Standard criteria donor | 24.5 | 29.4 | |
Expanded criteria donor | 10.9 | 11.8 | |
Pre-transplant dialysis (%) | 0.102 | ||
Preemptive | 15.3 | 22.1 | |
Hemodialysis | 68.6 | 47.1 | |
Peritoneal dialysis | 16.1 | 30.9 | |
Duration of dialysis (months) | 47.4 ± 52.1 | 44.1 ± 54.0 | 0.704 |
Re-transplantation | 6.8 | 7.4 | 0.883 |
ABO-incompatible (%) | 7.6 | 19.1 | 0.019 |
HLA mismatch (numbers) | 3.1 ± 1.5 | 3.1 ± 1.7 | 0.915 |
Calcineurin inhibitor (%) | 0.349 | ||
None | 2.5 | 5.9 | |
Cyclosporine | 13.6 | 8.8 | |
Tacrolimus | 83.9 | 85.3 | |
Induction regimen (%) | 0.108 | ||
None | 15.3 | 7.4 | |
Basliximab | 82.2 | 92.6 | |
Antithymocyte globulin | 2.5 | 0 | |
Desensitization (%) | 11.0 | 22.1 | 0.043 |
Diabetes mellitus (%) | 20.3 | 22.1 | 0.781 |
Hypertension (%) | 94.1 | 98.5 | 0.149 |
DMN for kidney failure (%) | 19.5 | 19.1 | 0.950 |
Positivity for CMV (%) | 57.6 | 60.3 | 0.722 |
Oral prophylactic antibiotics (%) | 14.4 | 10.3 | 0.420 |
Acute T cell-mediated rejection (%) | 66.9 | 61.8 | 0.475 |
Acute antibody-mediated rejection (%) | 9.3 | 11.8 | 0.596 |
Interstitial fibrosis and tubular atrophy (%) | 37.3 | 42.6 | 0.471 |
De novo donor-specific antibody (%) | 12.7 | 11.8 | 0.850 |